StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Physostigmine

HCID 178950866
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1217704-11-4
Standard-SMILES
CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C
InChIKey
PIJVFDBKTWXHHD-HIFRSBDPSA-N
Summenformel
C15H21N3O2
Durchschnittliche Molmasse
275,35 g/mol

Überblick

Physostigmine is a white, odorless, microcrystalline powder. Used as a cholinergic (anticholinesterase) agent and as a veterinary medication. (EPA, 1998)

Namen und Bezeichner

Bevorzugter Name
Physostigmine
IUPAC
[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate
Englischer Name
PIJVFDBKTWXHHD-RMLXDGKTSA-N
Summenformel
C15H21N3O2
Molmasse
275.35

Namen und Synonyme

physostigmineEserine57-47-6PhysostolEsromiotin(-)-physostigmineEzerinCalabarineFysostigminErserinecogmineeserin
Weitere Namen anzeigen
PIJVFDBKTWXHHD-RMLXDGKTSA-N
EserinumDTXSID3023471Eserolein, methylcarbamate (ester)MCV 4484MCV-4484NIH 10421NSC-307829U1VM840SP

Datenbank-Bezeichner

CAS
1217704-11-4
ChEMBL
CHEMBL537674、CHEMBL94
ChEBI
CHEBI:27953
UNII
9U1VM840SP
EC Number
200-332-8
Nikkaji
J4.579I

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
0,7
Polarare Oberfläche (TPSA)
44,8 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
2
Schwere Atome
20
Formalladung
0
Komplexität
403

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
SpringerMaterials PropertiesCrystal structure
LogP1.7
OdorODORLESS
Color/Form · 3 Einträge

ORTHORHOMBIC SPHENOIDAL PRISMS OR CLUSTERS OF LEAFLETS FROM ETHER OR BENZENE

WHITE MICROCRYSTALLINE POWDER

Colorless or pinkish crystals

Solubility · 5 Einträge

SLIGHTLY SOL IN WATER; SOL IN ALC, BENZENE, CHLOROFORM, OILS

VERY SOL IN DICHLOROMETHANE

Sol in ether

Sol in dilute acids

9.92e-01 g/L

Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Cholinesterase Inhibitors; Parasympathomimetics

Pharmaceuticals

DecompositionWhen heated to decomposition it emits toxic fumes of oxides of nitrogen.

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 6 Einträge

Danger

H300: Fatal if swallowed [Danger Acute toxicity, oral]

P260, P264, P270, P271, P284, P301+P316, P304+P340, P316, P320, P321, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Danger

H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]

P260, P264, P270, P271, P284, P301+P316, P304+P340, P316, P320, P321, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Gefahrenhinweise

Regulatory InformationThe New Jersey Worker and Community Right to Know Act requires public and private employers to provide information about hazardous substances at their workplaces. (N.J.S.A. 34:5A-1 et. seq.)
DOT LabelPoison
Fire HazardsIt is a slight fire hazard. When heated to decomposition it emits toxic fumes of nitrogen oxides. Keep from light and heat. (EPA, 1998)
Fire PotentialFire Hazard: Slight
Health Hazards · 1 Eintrag

Super toxic. Probable oral lethal dose is less than 5 mg/kg for a 70 kg (150 lb.) person. Material is a cholinesterase inhibitor. Effects of exposure may involve the respiratory, gastrointestinal, cardiovascular and central nervous systems. Death occurs due to respiratory paralysis or impaired cardiac function. Time to death may vary from 5 minutes to 24 hours, in severely poisoned patients, depending on factors such as the dose and route. Persons with asthma and/or persons that require drugs containing choline esters are at risk. (EPA, 1998)

FDA Requirements · 1 Eintrag

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 6 Einträge

V - Various

S - Sensory organs

QV - Various

QA - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

QS - Sensory organs

Pharmacodynamics · 1 Eintrag

Physostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor which effectively increases the concentration of acetylcholine at the sites of cholinergic transmission. Physostigmine is used to treat glaucoma. Because it crosses the blood-brain barrier, it is also used to treat the central nervous system effects of atropine overdose and other anticholinergic drug overdoses. Physostigmine can reverse both central and peripheral anticholinergia.

Mechanism of Action · 5 Einträge

Physostigmine inhibits acetylcholinesterase, the enzyme responsible for the breakdown of used acetylcholine. By interfering with the metabolism of acetylcholine, physostigmine indirectly stimulates both nicotinic and muscarinic receptors due to the consequential increase in available acetylcholine at the synapse.

CHARACTERISTIC PHARMACOLOGICAL EFFECTS OF ANTICHOLINESTERASE AGENTS ARE DUE PRIMARILY TO PREVENTION OF HYDROLYSIS OF ACETYLCHOLINE BY ACETYLCHOLINESTERASE @ SITES OF CHOLINERGIC TRANSMISSION. TRANSMITTER THUS ACCUMULATES, AND THE ACTION OF ACETYLCHOLINE THAT IS LIBERATED BY CHOLINERGIC IMPULSES OR THAT LEAKS FROM THE NERVE ENDING IS ENHANCED. /ACETYLCHOLINE/

... PHYSOSTIGMINE, A TERTIARY AMINE, EXERTS /MINIMAL/ EFFECTS NOT RELATED TO ACETYLCHOLINESTERASE INHIBITION. AT SUFFICIENTLY HIGH DOSAGE, HOWEVER, IT HAS DIRECT BLOCKING ACTION AT AUTONOMIC GANGLIA.

In chronic open-angle glaucoma, the exact mechanism by which miotics lower intraocular pressure is not precisely known; however, contraction of the ciliary muscle apparently opens the intratubular spaces and facilitates aqueous humor outflow.

Antagonizes action of anticholinergics, which block the post-synaptic receptor sites of acetylcholine, by inhibiting the destruction of acetylcholine by acetylcholinesterase, thereby increasing the concentration of acetylcholine at sites of cholinergic transmission.

Metabolism/Metabolites · 4 Einträge

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Melting Point · 5 Einträge

221 to 223 °F (EPA, 1998)

105-106 °C (ALSO AN UNSTABLE, LOW MELTING FORM, 86-87 °C)

Acicular crystals; mp: 185-187 °C; one gram dissolves in 75 ml water at 25 °C (pH of 0.5% aq soln 5.8), in 16 ml water at 80 °C, in 16 ml alcohol, 5 ml boiling alcohol, in 6 ml chloroform, 250 ml ether. /Physostigmine salicylate/

Deliquescent scales; mp: 140 °C (after drying at 100 °C); one gram dissolves in 0.4 ml alcohol, 4 ml water (pH of 0.05M soln 4.7), 1200 ml ether; the solns are more prone to change color than those of the salicylate. /Physostigmine sulfate/

105.5 °C

Vapor Pressure0.00001 [mm Hg] @25 °C
Optical RotationSPECIFIC OPTICAL ROTATION @ 17 °C/D= -76 DEG (CONCENTRATION BY VOLUME = 1.3 GIN 100 ML CHLOROFORM); @ 25 °C/D= -120 DEG (BENZENE)
Physical Description · 2 Einträge

Physostigmine is a white, odorless, microcrystalline powder. Used as a cholinergic (anticholinesterase) agent and as a veterinary medication. (EPA, 1998)

Solid

Physikochemische Eigenschaften

Löslichkeit
Chloroform (Slightly), Methanol (Very Slightly)
Aggregatzustand
Solid
Farbe
Pale Beige to Light Beige

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Reactive GroupAmines, Phosphines, and Pyridines
Air and Water ReactionsNo rapid reaction with air. No rapid reaction with water.
CERCLA Reportable Quantities · 1 Eintrag

Releases of CERCLA hazardous substances are subject to the release reporting requirement of CERCLA section 103, codified at 40 CFR part 302, in addition to the requirements of 40 CFR part 355. Physostigmine is an extremely hazardous substance (EHS) subject to reporting requirements when stored in amounts in excess of its threshold planning quantity (TPQ) of 100/10,000 lbs.

Hazard Classes and Categories · 4 Einträge

Acute Tox. 2 (100%)

Acute toxicity - category 2

Acute toxicity (Oral) - Category 1

Acute Tox. 2 *

Hazardous Reactivities and IncompatibilitiesBenzalkonium chloride is incompatible with physostigmine salicylate but is compatible with physostigmine sulfate.

Sicherheit und Schutzausrüstung

Fire FightingThis is a carbamate pesticide. As for carbamate pesticides, wear self-contained breathing apparatus when fighting fires.
First AidNote: Physostigmine is a cholinesterase inhibitor.
Storage Conditions · 5 Einträge

SOLNS SHOULD BE KEPT WELL CLOSED IN LIGHT-RESISTANT, ALKALI-FREE GLASS CONTAINER& USED WITHIN A WK. /PHYSOSTIGMINE SALICYLATE/

Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight, light-resistant container. Protect from freezing. /Physostigmine salicylate ophthalmic solution USP/

Packaging and storage: Store below 40 °C ( 104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Protect from freezing. /Physostigmine sulfate ophthalmic ointment USP/

Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Protect from light. Protect from freezing. /Physostigmine salicylate USP/

For more Storage Conditions (Complete) data for PHYSOSTIGMINE (6 total), please visit the HSDB record page.

Nonfire Spill Response · 1 Eintrag

This is a carbamate pesticide. As for other carbamate pesticides, avoid breathing dusts, and fumes from burning materials. Keep upwind. Avoid bodily contact with the material. Wash away any material which may have contacted the body with copious amounts of water or soap and water. (EPA, 1998)

Isolation and EvacuationExcerpt from ERG Guide 154 [Substances - Toxic and/or Corrosive (Non-Combustible)]:
Protective Action Criteria (PAC) · 3 Einträge

0.41 [mg/m3]

4.5 [mg/m3]

27 [mg/m3]

Personal Protective Equipment (PPE) · 1 Eintrag

For emergency situations, wear a positive pressure, pressure-demand, full facepiece self-contained breathing apparatus (SCBA) or pressure- demand supplied air respirator with escape SCBA and a fully-encapsulating, chemical resistant suit. (EPA, 1998)

Toxikologische Informationen

Interactions · 5 Einträge

ACTIONS OF ANTICHOLINESTERASE AGENTS ON AUTONOMIC EFFECTOR CELLS & ON CORTICAL & SUBCORTICAL SITES IN CNS, WHERE RECEPTORS ARE LARGELY OF MUSCARINIC TYPE, ARE BLOCKED BY ATROPINE. /ANTI-CHOLINESTERASE AGENTS/

VARIOUS ACTIONS OF ANTI-CHOLINESTERASE AGENTS ON SKELETAL MUSCLE ARE AUGMENTED BY EPINEPHRINE OR EPHEDRINE ... & BLOCKED BY D-TUBOCURARINE. /ANTICHOLINESTERASEAGENTS/

SUFFICIENT CONCN OF ... PHYSOSTIGMINE ... PREVENTS ALKYLPHOSPHORYLATION OF ACETYLCHOLINESTERASE BY DIISOPROPYLFLUORO PHOSPHATE OCCUPATION OF ACTIVE SITES OF /CHOLINESTERASE/ ENZYME BY THE SHORTER ACTING DRUG PREVENTS ... ALKYLPHOSPHORYLATION BY ORGANOPHOSPHORUS CMPD ... IN VITRO & IN VIVO.

TOXOGONIN GIVEN 15 MIN PRIOR TO ADMIN OF PHYSOSTIGMINE CAUSED REDN IN TOXICITY TO MICE OF PHYSOSTIGMINE. PRALIDOXIME MESYLATE ALSO CAUSED SLIGHT REDN.

For more Interactions (Complete) data for PHYSOSTIGMINE (9 total), please visit the HSDB record page.

Adverse EffectsSignificant adverse effects seen with the use of physostigmine are rarely reported and are most commonly related to overdose or seen in patients who have contraindications.
Toxicity SummaryThe antidote for physostigmine toxicity is atropine. Atropine is in the tropane alkaloid class and is an anticholinergic medication used as an antidote to pesticide and nerve agent poisonings.
Natural Pollution Sources · 2 Einträge

Physostigmine, an indirect-acting parasympathomimetic agent, is an alkaloid usually obtained from the dried ripe seeds of Physostigma venenosum.

FROM CALABAR BEANS, THE SEEDS OF THE VINE PHYSOSTIGMA VENENOSUM BALF, LEGUMINOSAE.

Human Toxicity Excerpts · 5 Einträge

GI SYMPTOMS OCCUR EARLIEST AFTER INGESTION, & INCL ANOREXIA, NAUSEA & VOMITING, ABDOMINAL CRAMPS, & DIARRHEA. WITH PERCUTANEOUS ABSORPTION OF LIQ, LOCALIZED SWEATING & MUSCULAR FASCICULATION IN IMMEDIATE VICINITY ARE GENERALLY EARLIEST MANIFESTATIONS. /ANTI-CHOLINESTERASE AGENTS/

EFFECTS ON CNS INCL CONFUSION, ATAXIA, SLURRED SPEECH, LOSS OF REFLEXES, CHEYNE-STOKES RESPIRATION, GENERALIZED CONVULSIONS, COMA, & CENTRAL RESP PARALYSIS. ... TIME OF DEATH AFTER SINGLE ACUTE EXPOSURE ... 5 MIN TO NEARLY 24 HR, DEPENDING UPON DOSE, ROUTE ... CAUSE OF DEATH ... RESP FAILURE ... /&/ SECONDARY CARDIOVASCULAR COMPONENT. /ANTI-CHOLINESTERASE AGENTS/

AFTER LOCAL EXPOSURE TO VAPORS OR ... INHALATION, OCULAR PAIN & RESP EFFECTS GENERALLY APPEAR FIRST. OCULAR ... INCL MARKED MIOSIS, OCCULAR PAIN, CONJUNCTIVAL CONGESTION, DIMINISHED VISION, CILIARY SPASM, & BROW ACHE. IN ADDITION TO RHINORRHEA AND HYPEREMIA OF THE UPPER RESP TRACT, RESP EFFECTS CONSIST OF "TIGHTNESS" IN CHEST & WHEEZING RESP, CAUSED BY ... BRONCHOCONSTRICTION & INCR BRONCHIAL SECRETION. /ANTI-CHOLINESTERASE AGENTS/

NICOTINIC ACTIONS @ NEUROMUSCULAR JUNCTIONS OF SKELETAL MUSCLE ... FATIGABILITY & GENERALIZED WEAKNESS, INVOLUNTARY TWITCHINGS ... SEVERE WEAKNESS & PARALYSIS; A CENTRAL COMPONENT OF ACTION CONTRIBUTES TO SOME OF THESE EFFECTS. THE MOST SERIOUS CONSEQUENCE ... IS PARALYSIS OF RESPIRATORY MUSCLES. /ANTI -CHOLINESTERASE AGENTS/

For more Human Toxicity Excerpts (Complete) data for PHYSOSTIGMINE (18 total), please visit the HSDB record page.

Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

physostigmine

DILI Negative

Intravenous

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 2 Einträge

INJECTING 0.05 TO 15.0 MG INTO THE YOLK SAC DURING THE FIRST 12 DAYS OF INCUBATION PRODUCED SEVERE VERTEBRAL DEFECTS AND MICROMELIA IN CHICKS. /ANOTHER EXPT/ USED 0.05 MG AT 26 HR TO PRODUCE BRACHYMELIA AND SPINA BIFIDA IN THE CHICK.

Two consecutive im doses of physostigmine (300 ug/kg, at 0 and 120 min) were given to male Sprague Dawley rats and the effects on acetylcholine, choline, the activity of choline acetyltransferase, and the release of acetylcholine from slices of caudate nucleus were studied. Peak inhibition of cholinesterase was moderate (65%) at 15 min after the first physostigmine administration. The time course and extent of inhibition of cholinesterase after the first and second administration of physostigmine followed a similar pattern. Fifteen min after the second administration of physostigmine, inhibition of cholinesterase was 60%; the activity recovered to control levels at 120 min. After the first administration of physostigmine, levels of acetylcholine incr by 70%. The peak value of acetylcholine was reached at 15 min. Acetylcholine returned almost to control levels at 60 min after treatment. The incr in the level of acetylcholine in brain seen with the second administration of physostigmine was of the same order and duration as that seen after the first administration.

Antidote and Emergency Treatment · 1 Eintrag

Recommended treatment for physostigmine overdose includes: Maintenance of open airway (possible suction of bronchial secretions); use of assisted respiration. Monitoring of cardiac function. Intravenous administration of atropine sulfate in doses of 2 to 4 mg; may be repeated every 3 to 10 minutes, if necessary to control muscarinic effects. Intravenous administration of pralidoxime chloride at a rate of 50 to 100 mg per minute, to counteract ganglionic and skeletal muscle effects. Treatment of convulsions or shock as appropriate.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Regulatorische Informationen

FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

CERCLA Reportable Quantities · 1 Eintrag

Releases of CERCLA hazardous substances are subject to the release reporting requirement of CERCLA section 103, codified at 40 CFR part 302, in addition to the requirements of 40 CFR part 355. Physostigmine is an extremely hazardous substance (EHS) subject to reporting requirements when stored in amounts in excess of its threshold planning quantity (TPQ) of 100/10,000 lbs.

Quickly hydrolyzed by cholinesterases

/PHYSOSTIGMINE/ IS LARGELY DESTROYED IN BODY, MAINLY BY HYDROLYTIC CLEAVAGE @ ESTER LINKAGE BY PLASMA ESTERASES. ... IN MAN, 1 MG DOSE ... INJECTED SC IS LARGELY DESTROYED IN 2 HR.

/PHYSOSTIGMINE/ COMBINES WITH THE ENZYME AT THE ESTERATIC SITE TO YIELD THE INACTIVE METHYLCARBAMOYL ENZYME.

Rapidly hydrolyzed by cholinesterases.

MeSH Pharmacological Classification · 2 Einträge

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here.

Absorption, Distribution and Excretion · 5 Einträge

PHYSOSTIGMINE IS READILY ABSORBED FROM GI TRACT, SC TISSUES, & MUCOUS MEMBRANES. ... RENAL EXCRETION PLAYS ONLY MINOR ROLE IN ITS DISPOSAL.

PHYSOSTIGMINE, A TERTIARY AMINE, CROSSES THE BLOOD-BRAIN BARRIER IN CONTRAST TO THE QUATERNARY ANTI-ACETYL CHOLINESTERASE DRUGS. /ACETYLCHOLINESTERASE/

Easily penetrates the blood-brain barrier.

Time to peak effect: iv within 5 min; duration of action: iv approximately 1 to 2 hr.

Very small amounts eliminated in urine; largely destroyed in body by hydrolysis.

Cellular LocationsCytoplasm

Verwendung und Herstellung

Uses · 2 Einträge

MEDICATION

MEDICATION (VET):

Formulations/Preparations · 5 Einträge

PHYSOSTIGMINE IS GENERALLY USED AS SALICYLATE OR SULFATE SALT; SALICYLATE HAS ADVANTAGE OF BEING LESS DELIQUESCENT ... ADDITION OF FEW GRAINS BORIC ACID TO SOLN OF SALT ... INHIBIT FORMATION OF RED DECOMP PRODUCT ... .

PHYSOSTIGMINE, USP (ESERINE), PHYSOSTIGMINE SALICYLATE, USP, & PHYSOSTIGMINE SULFATE, USP ARE AVAILABLE AS CRYSTALLINE POWDERS FOR COMPOUNDING ORAL & PARENTERAL PREPN IN SUITABLE DOSAGE FORMS.

PHYSOSTIGMINE SALICYLATE (ANTILIRIUM) IS AVAILABLE AS A SOLUTION (1 MG/ML) FOR INJECTION. PHYSOSTIGMINE SULFATE OPHTHALMIC OINTMENT (0.25%) & PHYSOSTIGMINE SALICYLATE OPHTHALMIC SOLUTION (0.25% & 0.5%), ARE ALSO AVAILABLE.

Ophthalmic solution (as the salicylate), 0.25% and 0.5%. Ophthalmic ointment (as the sulfate), 0.25%. Ampules and syringes (as the salicylate), 1 mg/ml.

For more Formulations/Preparations (Complete) data for PHYSOSTIGMINE (8 total), please visit the HSDB record page.

Use ClassificationPharmaceuticals
General Manufacturing Information · 3 Einträge

Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-methylcarbamate), (3aS,8aR)-: ACTIVE

THE VIABILITY OF THE CONDITIONED FLAVOR AVERSION TEST AS A BEHAVIORAL INDEX OF THE TOXICITY OF PHYSOSTIGMINE WAS EVALUATED IN A SERIES OF THREE EXPERIMENTS. IT WAS CONCLUDED THAT THE FLAVOR AVERSION TEST IS A SIMPLE AND SENSITIVE BEHAVIORAL MEASURE OF TOXICITY.

Available as the salicylate and sulfate.